Rezolute, Inc.

NASDAQ:RZLT

Biotechnology

Healthcare
$4.25 +6.16%

+$0.30 today

Market cap
$411.10M
Beta
0.65
P/E (TTM)
-6.5
EPS (TTM)
-$0.78
52W Low $1.07High $11.46

Volume 2.93M

Average 2.03M

RZLT Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Rezolute, Inc.NASDAQ: RZLT

Weighted Avg Shares (Diluted) · Q3 FY2026 · quarter ended Mar 2026

Weighted avg shares (diluted) grows, but more slowly than its trailing trend

Q3 FY2026 weighted avg shares (diluted) of 104.04M shares rose 48.6% year over year, behind the +55.6% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +57.4% a year.

Context

  • Weighted avg shares (diluted) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +48.6% toward the trailing-twelve-month pace of +55.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
104.04M+0.3% QoQ
Last fiscal yearJun 2025
76M+47.7% YoY
LTMMar 2026
101.37M+55.6% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+48.6%——
1 year+47.7%——
3-year CAGR+57.4%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
76M USD
Year-over-year change
+47.7%
4-year CAGR
+77.4%

Weighted Avg Shares (Diluted) vs competitors

How RZLT compares with its peers on the latest reported figures

  • RZLT's LTM Mar 2026 weighted avg shares (diluted) of 101.37M shares is the highest of the 5 companies compared; the peer median is 63.69M shares.
  • Its year-over-year change of +55.6% is the highest of 5, against a peer median of +3.2%.
  • Over three fiscal years its annual growth of +57.4% compares with a peer median of +12.2%.
RZLT Competitors Peer median
Weighted Avg Shares (Diluted) for RZLT and competitors
Company Period LTM YoY 3-year CAGR
RZLTRezolute, Inc.LTM Mar 2026101.37M +55.6%+57.4%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 202699.68M +6.6%+12.1%
PHARPharming Group N.V.LTM Mar 202669.93M -1.6%-5.4%
ZVRAZevra Therapeutics, Inc.LTM Mar 202657.44M +16.4%+18.4%
RLYBRallybio CorporationLTM Mar 20265.55M -0.3%+12.3%
Peer median (excluding RZLT) 63.69M+3.2%+12.2%

Competitors are the stored peer set for RZLT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jun 2021
FY2022
Jun 2022
FY2023
Jun 2023
FY2024
Jun 2024
FY2025
Jun 2025
Revenue00000
Cost of Revenue13K0000
Gross Profit(13K)0000
Gross Margin—————
Research & Development14.99M32.49M43.81M55.74M61.53M
Selling, General & Admin7.91M9.36M12.18M14.68M18.37M
Operating Expenses22.88M41.84M55.99M70.42M79.89M
Depreciation & Amortization13K13K30K36K31K
EBITDA(20.51M)(39.24M)(51.76M)(68.42M)(74.38M)
EBITDA Margin—————
Operating Income(22.89M)(41.84M)(55.99M)(70.42M)(79.89M)
Operating Margin—————
Interest Income63K80K4.21M4.87M5.48M
Interest Expense375K1.81M000
Other Income / Expenses1.99M783K4.2M1.96M5.48M
Income Before Tax(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(20.9M)(41.06M)(51.79M)(68.46M)(74.41M)
Net Margin—————
EPS (Basic)(2.72)(2.26)(1.01)(1.33)(0.98)
EPS (Diluted)(2.72)(2.32)(1.01)(1.33)(0.98)
Weighted Avg Shares7.67M18.2M51.19M51.47M76M
Weighted Avg Shares (Diluted)7.67M19.49M51.19M51.47M76M

Rezolute, Inc.

NASDAQ:RZLT

Intrinsic Alpha fair value

Locked

Current Price

$4.25

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.